CN113543788A - 一种tlr7激动剂的固体药物组合物 - Google Patents
一种tlr7激动剂的固体药物组合物 Download PDFInfo
- Publication number
- CN113543788A CN113543788A CN202080019228.9A CN202080019228A CN113543788A CN 113543788 A CN113543788 A CN 113543788A CN 202080019228 A CN202080019228 A CN 202080019228A CN 113543788 A CN113543788 A CN 113543788A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- solid pharmaceutical
- mixture
- amount
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 162
- 239000007787 solid Substances 0.000 title claims abstract description 132
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 153
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 120
- 150000001875 compounds Chemical class 0.000 claims description 105
- 239000003085 diluting agent Substances 0.000 claims description 84
- 229920000881 Modified starch Polymers 0.000 claims description 79
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 70
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 70
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 70
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 70
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 66
- 229920002472 Starch Polymers 0.000 claims description 63
- 239000000314 lubricant Substances 0.000 claims description 63
- 239000008107 starch Substances 0.000 claims description 63
- 235000019698 starch Nutrition 0.000 claims description 63
- 235000019359 magnesium stearate Nutrition 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 59
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 56
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 56
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 54
- 238000002156 mixing Methods 0.000 claims description 54
- 239000011734 sodium Substances 0.000 claims description 52
- 229910052708 sodium Inorganic materials 0.000 claims description 50
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 49
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 41
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 38
- 239000007884 disintegrant Substances 0.000 claims description 33
- 239000011230 binding agent Substances 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 28
- 238000007907 direct compression Methods 0.000 claims description 26
- 229960003943 hypromellose Drugs 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 22
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 22
- 239000001856 Ethyl cellulose Substances 0.000 claims description 21
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 21
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical class [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 21
- 229920001249 ethyl cellulose Polymers 0.000 claims description 21
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 21
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 21
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 21
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 21
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 20
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 20
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 20
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 20
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 20
- 229920000609 methyl cellulose Polymers 0.000 claims description 20
- 235000010981 methylcellulose Nutrition 0.000 claims description 20
- 239000001923 methylcellulose Substances 0.000 claims description 20
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 19
- 229930195725 Mannitol Natural products 0.000 claims description 19
- 239000008101 lactose Substances 0.000 claims description 19
- 239000000594 mannitol Substances 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 19
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 19
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 19
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 17
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 17
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 17
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 15
- 239000008119 colloidal silica Substances 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 239000000853 adhesive Substances 0.000 claims description 13
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 12
- 238000003801 milling Methods 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 235000001465 calcium Nutrition 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 4
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical class [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Chemical class 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 229960004274 stearic acid Drugs 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 229940033134 talc Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 229940057948 magnesium stearate Drugs 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 12
- VMDGIQUJSYPMLF-UHFFFAOYSA-N C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N Chemical compound C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N VMDGIQUJSYPMLF-UHFFFAOYSA-N 0.000 abstract description 3
- 229940032147 starch Drugs 0.000 description 54
- 238000009826 distribution Methods 0.000 description 16
- 229960001375 lactose Drugs 0.000 description 16
- 102000002689 Toll-like receptor Human genes 0.000 description 15
- 108020000411 Toll-like receptor Proteins 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 238000007873 sieving Methods 0.000 description 9
- 239000012535 impurity Substances 0.000 description 8
- 238000007908 dry granulation Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 229960001855 mannitol Drugs 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 4
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229910002018 Aerosil® 300 Inorganic materials 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- -1 and the like) Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种TLR7激动剂2‑丁氧基‑7‑(4‑(吡咯烷‑1‑基甲基)苄基)‑5H‑吡咯并[3,2‑d]嘧啶‑4‑胺的固体药物组合物、其制备方法及其医药用途，所述的固体药物组合物具有优良的稳定性和溶出性质。
Description
PCT国内申请，说明书已公开。
Claims (20)
- PCT国内申请，权利要求书已公开。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410053287.8A CN118045051A (zh) | 2019-04-23 | 2020-04-23 | 一种tlr7激动剂的固体药物组合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019103268999 | 2019-04-23 | ||
| CN201910326899 | 2019-04-23 | ||
| PCT/CN2020/086301 WO2020216274A1 (zh) | 2019-04-23 | 2020-04-23 | 一种tlr7激动剂的固体药物组合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410053287.8A Division CN118045051A (zh) | 2019-04-23 | 2020-04-23 | 一种tlr7激动剂的固体药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113543788A true CN113543788A (zh) | 2021-10-22 |
| CN113543788B CN113543788B (zh) | 2023-12-19 |
Family
ID=72940865
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080019228.9A Active CN113543788B (zh) | 2019-04-23 | 2020-04-23 | 一种tlr7激动剂的固体药物组合物 |
| CN202410053287.8A Pending CN118045051A (zh) | 2019-04-23 | 2020-04-23 | 一种tlr7激动剂的固体药物组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410053287.8A Pending CN118045051A (zh) | 2019-04-23 | 2020-04-23 | 一种tlr7激动剂的固体药物组合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220184085A1 (zh) |
| EP (1) | EP3949967A4 (zh) |
| JP (1) | JP2022530444A (zh) |
| KR (1) | KR20220004098A (zh) |
| CN (2) | CN113543788B (zh) |
| AU (1) | AU2020263448A1 (zh) |
| CA (1) | CA3137202A1 (zh) |
| SG (1) | SG11202111488YA (zh) |
| TW (1) | TW202103704A (zh) |
| WO (1) | WO2020216274A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4316518A1 (en) | 2021-03-29 | 2024-02-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Drug combination of toll-like receptor 7 agonist and anti-pd-l1 antibody |
| KR20220142378A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 고형 제제의 제조 방법 |
| CN117202893A (zh) * | 2021-04-14 | 2023-12-08 | 株式会社Lg化学 | 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA032824B1 (ru) | 2014-08-15 | 2019-07-31 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107550875A (zh) * | 2017-08-21 | 2018-01-09 | 赵剑锋 | 一种稳定的非诺贝酸片及其制备方法 |
| CN113747899B (zh) * | 2019-03-15 | 2023-11-21 | 正大天晴药业集团股份有限公司 | 用于治疗乙型肝炎的Toll样受体激动剂 |
-
2020
- 2020-04-23 KR KR1020217037645A patent/KR20220004098A/ko active Search and Examination
- 2020-04-23 EP EP20795435.5A patent/EP3949967A4/en active Pending
- 2020-04-23 AU AU2020263448A patent/AU2020263448A1/en active Pending
- 2020-04-23 WO PCT/CN2020/086301 patent/WO2020216274A1/zh unknown
- 2020-04-23 CN CN202080019228.9A patent/CN113543788B/zh active Active
- 2020-04-23 SG SG11202111488YA patent/SG11202111488YA/en unknown
- 2020-04-23 TW TW109113649A patent/TW202103704A/zh unknown
- 2020-04-23 CA CA3137202A patent/CA3137202A1/en active Pending
- 2020-04-23 JP JP2021563173A patent/JP2022530444A/ja active Pending
- 2020-04-23 CN CN202410053287.8A patent/CN118045051A/zh active Pending
- 2020-04-23 US US17/594,439 patent/US20220184085A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 黄朝霞: "粉末直接压片工艺的进展" * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022530444A (ja) | 2022-06-29 |
| EP3949967A1 (en) | 2022-02-09 |
| US20220184085A1 (en) | 2022-06-16 |
| CN113543788B (zh) | 2023-12-19 |
| AU2020263448A1 (en) | 2021-11-18 |
| EP3949967A8 (en) | 2022-09-07 |
| WO2020216274A1 (zh) | 2020-10-29 |
| CN118045051A (zh) | 2024-05-17 |
| CA3137202A1 (en) | 2020-10-29 |
| EP3949967A4 (en) | 2023-01-18 |
| TW202103704A (zh) | 2021-02-01 |
| KR20220004098A (ko) | 2022-01-11 |
| SG11202111488YA (en) | 2021-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11413295B2 (en) | Oral preparation of obeticholic acid | |
| CN113543788B (zh) | 一种tlr7激动剂的固体药物组合物 | |
| KR101840182B1 (ko) | 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물 | |
| KR20090016611A (ko) | 메만틴의 약학 조성물 | |
| WO2012061833A1 (en) | Compositions and methods for treating myelofibrosis | |
| WO2015189386A1 (en) | Composition with a high drug load of sofosbuvir | |
| JP2023175743A (ja) | 難溶性の塩基性薬剤を含有する医薬組成物 | |
| TW201442712A (zh) | 有機化合物之調配物 | |
| WO2018095403A1 (zh) | 一种吡啶酮类衍生物药物组合物及其制备方法 | |
| TWI794214B (zh) | 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物 | |
| JP6321131B2 (ja) | アムロジピン含有配合錠の溶出性改善方法 | |
| KR101809886B1 (ko) | 소형화된 클래리트로마이신 경구투여 제제 | |
| KR101944085B1 (ko) | 발사르탄 함유 고형 경구제형 및 그 제조방법 | |
| WO2022100641A1 (zh) | 包含egfr抑制剂的药物组合物及其制备方法 | |
| WO2022042646A1 (zh) | 盐酸鲁拉西酮组合物及其制备方法 | |
| JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
| EP4238555A2 (en) | Immediate release fixed-dose combination of memantine and donepezil | |
| TW202416999A (zh) | 包含 5-乙基-4-甲基-n-[4-[(2s)嗎啉-2-基]苯基]-1h-吡唑-3-甲醯胺的醫藥組成物 | |
| TW201607568A (zh) | 包含１－［６－（嗎啉－４－基）嘧啶－４－基］－４－（１ｈ－１，２，３－三唑－１－基）－１ｈ－吡唑－５－醇鈉之醫藥劑型 | |
| EP2749271A1 (en) | Optimized manufacturing method and pharmaceutical formulation of imatinib | |
| CN108721241A (zh) | 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法 | |
| CN105878201A (zh) | 托匹司他延长释放制剂 | |
| JP2017200958A (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
| WO2017114597A1 (en) | Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide | |
| JP2004091373A (ja) | 分解に対する安定性及び含量均一性に優れたメシル酸ペルゴリド含有製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060520 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |